Logo

Embark Scientific Buys Mouse Genotyping Assets from MendelWorks

Jan 03, 2008
NEW YORK (GenomeWeb News) – Genomics services company Embark Scientific has purchased mouse genotyping assets from MendelWorks, an Identigene spin-off, for an undisclosed sum, Embark said earlier this week.
 
Austin, Tex.-based Embark said the deal will help increase its mouse genotyping capacity and its animal genotyping market share. The added capacity includes PCR and real-time PCR-based genotyping, gene expression, and RNA expression analysis, the company said.
 
In addition to mouse genotyping, Embark offers DNA sequencing, RNA expression analysis, assay development, and lab consulting services to clients in government, academia, and in industry.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.